Prize4Life, a Cambridge non-profit focused on advancing research into cures for ALS, has awarded a prize of $1 million to Dr. Seward Rutkove, Chief of the Division of Neuromuscular Disease at Beth Israel Deaconess Medical Center and associate professor of neurology at Harvard Medical School.

Rutkove discovered a new biomarker for ALS, also known as Lou Gehrig’s disease, that will help researchers measure whether a new potential treatment is working on patients. There is currently just one treatment on the market, called Rilutek, made by France-based Sanofi-aventis.

SOURCE